A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after prior EGFR-TKI therapy.

NCT Number	NCT07669051
Lead Sponsor	Shandong Cancer Hospital and Institute
Conditions	NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment	36 participants
Start Date	2026-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2029-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-25